# T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

> **NCT00008528** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 525 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Enfuvirtide

## Key facts

- **NCT ID:** NCT00008528
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 525 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00008528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00008528, "T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00008528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*